Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHEST-1 long-term extension of BAY 63-2521 in CTEPH
NL-OMON37076Phase 3Withdrawn
- Sponsor
- Bayer
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of riociguat in chronic thromboembolic pulmonary hypertension (CTEPH), sponsored by Bayer. Planned start Nov 2008; status: withdrawn.
02
Drugs
riociguat
03
Conditions
chronic thromboembolic pulmonary hypertension (CTEPH)
Beyond the preview
Go deeper on NL-OMON37076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37076.